Marble Wealth LLC Acquires New Position in Johnson & Johnson $JNJ

Key Points

• Marble Wealth LLC initiated a new position in Johnson & Johnson, buying 14,254 shares worth about $2.95 million in the fourth quarter.
• Wall Street sentiment remains broadly positive: multiple analysts raised targets or reiterated bullish ratings, and the stock’s consensus view is still “Moderate Buy” with an average price target of $253.04.
• Johnson & Johnson recently reported solid results, beating EPS and revenue expectations, and it also raised its quarterly dividend to $1.34 per share, supporting its appeal as an income stock.

Marble Wealth LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 14,254 shares of the company's stock, valued at approximately $2,950,000.

Several other institutional investors also recently bought and sold shares of JNJ. Brighton Jones LLC grew its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank grew its position in Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC grew its position in Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after purchasing an additional 692 shares during the last quarter. Wealth Group Ltd. grew its position in Johnson & Johnson by 12.8% during the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock valued at $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. grew its position in Johnson & Johnson by 9.8% during the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock valued at $11,255,000 after purchasing an additional 6,584 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. Leerink Partners raised shares of Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price target on the stock in a report on Wednesday, May 13th. Daiwa Securities Group raised their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an "outperform" rating in a report on Thursday, April 16th. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Johnson Rice raised shares of Johnson & Johnson from a "hold" rating to an "outperform" rating in a report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $253.04.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: CNBC’s Jim Cramer pointed to Johnson & Johnson as one of five stocks to buy for diversification outside the AI trade, which could attract investors looking for lower-volatility, defensive exposure. Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
• Positive Sentiment: Scotiabank reiterated its Buy rating on Johnson & Johnson, reinforcing Wall Street confidence in the company’s earnings durability and dividend appeal. Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
• Positive Sentiment: Several articles highlighted JNJ as one of the best dividend-paying stocks to own, which can support the stock as investors favor income and defensive healthcare names. Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?
• Neutral Sentiment: Recent commentary also questioned whether Johnson & Johnson’s strong one-year rally leaves limited upside near current levels, suggesting valuation could temper enthusiasm. Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?
• Neutral Sentiment: A Motley Fool piece argued JNJ’s effort to challenge AbbVie’s growth driver should not alarm AbbVie shareholders, implying the competitive angle is not a major near-term negative for Johnson & Johnson itself. Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $223.00 on Wednesday. The firm's 50 day moving average price is $232.75 and its 200-day moving average price is $225.29. Johnson & Johnson has a twelve month low of $149.04 and a twelve month high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $536.81 billion, a PE ratio of 25.78, a price-to-earnings-growth ratio of 2.19 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to analysts' expectations of $23.60 billion. During the same quarter in the prior year, the business earned $2.77 EPS. The business's quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a $1.34 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson's dividend payout ratio (DPR) is currently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.